Bioasis Announces $200,000 Non-Brokered Private Placement
Rhea-AI Summary
Bioasis Technologies Inc. (OTCQB:BIOAF) has completed a non-brokered private placement, issuing 400,000 common shares at $0.50 each, resulting in gross proceeds of $200,000. The shares will have a four-month hold period in line with securities regulations. Bioasis focuses on developing its proprietary xB3 ™ platform technology to deliver therapeutics across the blood-brain barrier, targeting central nervous system disorders with significant unmet medical needs, including brain cancers and neurodegenerative diseases.
Positive
- Completed a private placement raising $200,000.
- Proprietary xB3 ™ platform targets high unmet medical needs in CNS disorders.
Negative
- None.
News Market Reaction – BIOAF
In the trading session that priced this news, BIOAF gained 16.62%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GUILFORD, Conn., Jan. 29, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has completed a non-brokered private placement of 400,000 common shares to a Canadian family office at a price of
The common shares issued pursuant to the private placement are subject to a four month hold period in accordance with applicable securities laws.
On behalf of the Board of Directors of Bioasis Technologies Inc.
Deborah Rathjen, Ph.D., Director and President & Chief Executive Officer
deborah@bioasis.us
+1 203 533 7082
About Bioasis
Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3 ™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. The company maintains headquarters in Guilford, Conn., United States. Bioasis trades on the TSX Venture Exchange under the symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For more information about the company, please visit www.bioasis.us.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.